Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone512-961-1891
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$130,000.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
Savara (NASDAQ:SVRA) Frequently Asked Questions
What is Savara's stock symbol?
Savara trades on the NASDAQ under the ticker symbol "SVRA."
How were Savara's earnings last quarter?
Savara Inc (NASDAQ:SVRA) announced its quarterly earnings data on Thursday, May, 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.05. View Savara's Earnings History.
When is Savara's next earnings date?
What price target have analysts set for SVRA?
5 brokers have issued 12-month target prices for Savara's stock. Their predictions range from $10.00 to $40.00. On average, they expect Savara's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 105.5% from the stock's current price. View Analyst Price Targets for Savara.
What is the consensus analysts' recommendation for Savara?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Savara.
What are Wall Street analysts saying about Savara stock?
Here are some recent quotes from research analysts about Savara stock:
- 1. According to Zacks Investment Research, "Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. " (5/17/2019)
- 2. LADENBURG THALM/SH SH analysts commented, "We believe IMPALA is likely to succeed given GM-CSF’s central role in aPAP, prior trial results and Molgradex’s confirmed low systemic exposure and safety profile. Encouragingly, nearly all eligible patients chose to enroll in the extension trial 26 as of 1Q’19)." (5/10/2019)
Has Savara been receiving favorable news coverage?
Media headlines about SVRA stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Savara earned a news impact score of -1.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days.
Who are some of Savara's key competitors?
Some companies that are related to Savara include Zogenix (ZGNX), Zai Lab (ZLAB), Prestige Consumer Healthcare (PBH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP), Innoviva (INVA), Cambrex (CBM), Esperion Therapeutics (ESPR), Heron Therapeutics (HRTX), Gossamer Bio (GOSS), Opko Health (OPK), Aimmune Therapeutics (AIMT), Corcept Therapeutics (CORT), Mallinckrodt (MNK) and Apellis Pharmaceuticals (APLS).
What other stocks do shareholders of Savara own?
Who are Savara's key executives?
Savara's management team includes the folowing people:
- Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
- Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
- David L. Lowrance, Chief Financial Officer (Age 50)
- Nevan C. Elam, Independent Director (Age 49)
- Richard J. Hawkins, Independent Director (Age 68)
- Joseph S. McCracken Ph.D., Independent Director (Age 64)
- Matthew Pauls J.D., Independent Director (Age 46)
- Yuri Pikover, Independent Director (Age 56)
Who are Savara's major shareholders?
Savara's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.13%), Northern Trust Corp (0.95%), Geode Capital Management LLC (0.91%), Alps Advisors Inc. (0.24%), Renaissance Technologies LLC (0.18%) and Charles Schwab Investment Management Inc. (0.17%). Company insiders that own Savara stock include David L Lowrance, Jaakko Taneli Jouhikainen, Joseph S Mccracken, Richard J Hawkins, Robert N Neville and Yuri Pikover. View Institutional Ownership Trends for Savara.
Which major investors are selling Savara stock?
SVRA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Oxford Asset Management LLP, Northern Trust Corp, BlackRock Inc., Trexquant Investment LP, Charles Schwab Investment Management Inc. and California State Teachers Retirement System. Company insiders that have sold Savara company stock in the last year include David L Lowrance, Jaakko Taneli Jouhikainen, Richard J Hawkins and Robert N Neville. View Insider Buying and Selling for Savara.
Which major investors are buying Savara stock?
SVRA stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, JPMorgan Chase & Co., Geode Capital Management LLC, MetLife Investment Advisors LLC, MetLife Investment Advisors LLC, Mesirow Financial Investment Management Inc., Metropolitan Life Insurance Co NY and State of Wisconsin Investment Board. Company insiders that have bought Savara stock in the last two years include David L Lowrance, Jaakko Taneli Jouhikainen, Joseph S Mccracken, Robert N Neville and Yuri Pikover. View Insider Buying and Selling for Savara.
How do I buy shares of Savara?
Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Savara's stock price today?
One share of SVRA stock can currently be purchased for approximately $11.19.
How big of a company is Savara?
Savara has a market capitalization of $400.94 million and generates $130,000.00 in revenue each year. The company earns $-61,520,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis.
What is Savara's official website?
How can I contact Savara?
Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, Austin TX, 78746. The company can be reached via phone at 512-961-1891 or via email at [email protected]
MarketBeat Community Rating for Savara (NASDAQ SVRA)
MarketBeat's community ratings are surveys of what our community members think about Savara and other stocks. Vote "Outperform" if you believe SVRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
